Lipocine (NASDAQ:LPCN) has been given a $3.00 price target by stock analysts at HC Wainwright in a research note issued on Friday, MarketBeat.com reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 75.44% from the company’s previous close.

LPCN has been the topic of a number of other research reports. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $11.00 target price on shares of Lipocine in a research report on Thursday. Canaccord Genuity downgraded Lipocine from a “buy” rating to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.50.

Lipocine (NASDAQ:LPCN) traded down $0.16 during trading hours on Friday, hitting $1.71. The company had a trading volume of 1,578,100 shares, compared to its average volume of 622,569. The firm has a market capitalization of $36.25, a P/E ratio of -1.78 and a beta of 0.11. Lipocine has a twelve month low of $1.67 and a twelve month high of $5.33.

Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new position in Lipocine during the second quarter worth about $300,000. Federated Investors Inc. PA grew its holdings in Lipocine by 9.2% during the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after purchasing an additional 7,429 shares during the period. P.A.W. Capital Corp bought a new position in Lipocine during the third quarter worth about $397,000. Ameriprise Financial Inc. grew its holdings in Lipocine by 18.2% during the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after purchasing an additional 24,000 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Lipocine by 39.7% during the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after purchasing an additional 155,110 shares during the period. Institutional investors and hedge funds own 22.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/13/hc-wainwright-reiterates-3-00-price-target-for-lipocine-lpcn.html.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.